Evotec

The deal expands Evotec's existing CRISPR licenses through the Broad Institute and adds to ERS's list of licensees for its gene editing technology.

Evotec will gain non-exclusive rights to Ncardia IP, including a broad panel of stem cell-derived cell lines for use in drug target discovery and testing.

Evotec will use Merck's collection of genetic reagents — including viral CRISPR and shRNA libraries — in target discovery programs.

Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification.

NEW YORK (GenomeWeb News) – Evotec said today that the CHDI Foundation has extended and expanded the two parties' collaboration on Huntington's disease research through 2017.

NEW YORK (GenomeWeb) – Evotec said this week that it has achieved a milestone in its protein biomarker work with Roche, as the drugmaker selected for phase I clinical trial use a response prediction marker developed through the two firms' collaboration.

NEW YORK (GenomeWeb News) – Evotec today said that it has forged an alliance with the Harvard Stem Cell Institute to identify compounds that can prevent or slow down the loss of motor neurons, a characteristic of amyotrophic lateral sclerosis.

While chemical proteomics has traditionally focused on pharmaceutical work, several recent collaborations suggest that the field is establishing a foothold within agricultural research, as well.

NEW YORK (GenomeWeb News) – Evotec and the Jain Foundation today said they have extended and expanded their 2012 research collaboration aimed at dysferlinopathy.
Terms of the expanded deal were not disclosed.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.